In rare and specialty therapeutics, access is rarely binary. A few patients are denied, then appeal, fight through peer-to-peers, file exceptions, and sometimes succeed. Most navigate friction from the start: prescriber restrictions, prior authorizations, step therapy, documentation hurdles, specialty pharmacy requirements, and renewal cycles that repeat at every fill. For chronic conditions, that friction never ends. It returns every month, every year, every formulary update, and it shows up as adherence loss, delayed launches, and outcomes the system was built to prevent.

Most of it traces back to a structural pattern: pharmaceutical policy and clinical evidence do not always line up. In rare and specialty markets, where every patient counts and every launch is high-stakes, those gaps compound quickly.

Marigolds AI works on that alignment problem.

Marigolds AI exists so that every patient prescribed a therapy can get it with the least friction possible, and stay on it.

Marigolds AI

Org chart

Teams

Offices

Marigolds AI

Org chart

Teams

Offices

Related companies